Ngomhla zi-5 kuJulayi, i-Novo Nordisk yethula isivivinyo somtholampilo sesigaba III somjovo we-CagriSema e-China, inhloso yakho okuwukuqhathanisa ukuphepha nokusebenza komjovo we-CagriSema ne-semeglutide ezigulini ezikhuluphele nezikhuluphele e-China.
Umjovo we-CagriSema uwukwelapha okuhlanganisiwe okuthatha isikhathi eside okusathuthukiswa yi-Novo Nordisk, izakhi eziyinhloko yi-GLP-1 (i-glucagon-like peptide-1) i-agonist smeglutide kanye ne-amylin analog cagrilintide esebenza isikhathi eside.Umjovo we-CagriSema ungafakwa ngaphansi kwesikhumba kanye ngesonto.
Inhloso eyinhloko kwakuwukuqhathanisa i-CagriSema (2.4 mg/2.4 mg) ne-semeglutide noma i-placebo kanye ngesonto ngaphansi kwesikhumba.I-Novo Nordisk imemezele imiphumela yocwaningo lwe-CagriSema yokwelapha isifo sikashukela sesigaba sesi-2, esifakazele ukuthi umphumela we-CagriSema we-hypoglycemic ungcono kunalowo we-semeglutide, futhi cishe u-90% wezifundo uzuze umgomo we-HbA1c.
Idatha ibonise ukuthi ngaphezu komphumela obalulekile we-hypoglycemic, mayelana nokulahlekelwa kwesisindo, umjovo we-CagriSema uphumelele kakhulu i-semeglutide (5.1%) ne-cagrilintide (8.1%) ngokulahlekelwa kwesisindo se-15.6%.
Umuthi omusha i-Tirzepatide uyi-agonist yokuqala emhlabeni egunyazwe masonto onke ye-GIP/GLP-1.Ihlanganisa imiphumela yama-incretins amabili ibe yi-molecule eyodwa ejovwa kanye ngesonto futhi iyisigaba esisha sokwelashwa kwesifo sikashukela sohlobo 2.I-Tirzepatide yagunyazwa yi-US Food and Drug Administration (FDA) ngoMeyi 2022 ukuze ithuthukise ukulawulwa kwe-glycemic (ngokwesisekelo sokudla nokuzivocavoca) kubantu abadala abanesifo sikashukela sohlobo 2 futhi okwamanje ivunyelwe e-European Union, Japan nakwamanye amazwe.
Ngomhla zi-5 kuJulayi, u-Eli Lilly wamemezela ucwaningo lwesigaba III se-SURPASS-CN-MONO mayelana nenkundla yokubhaliswa kwesilingo somtholampilo kanye nenkundla yokudalula ulwazi yokwelapha iziguli ezinesifo sikashukela sohlobo 2.I-SURPASS-CN-MONO iwucwaningo lwesigaba III olungahleliwe, olungaboni kabili, olulawulwa yi-placebo oluklanyelwe ukuhlola ukusebenza kahle nokuphepha kwe-tirzepatide monotherapy uma kuqhathaniswa ne-placebo kubantu abanesifo sikashukela sohlobo 2.Ucwaningo luhlele ukufaka iziguli ezingama-200 ezinesifo sikashukela sohlobo 2 ezazingasebenzisi noma yimaphi amaphilisi e-antidiabetic ezinsukwini ezingama-90 ngaphambi kokuvakasha koku-1 (ngaphandle kwezimo ezithile zomtholampilo, njengokugula okunzima, ukulaliswa esibhedlela, noma ukuhlinzwa okukhethekile, isikhathi esifushane (≤14 izinsuku) ukusetshenziswa kwe-insulin).
Isifo sikashukela sohlobo 2 kulindeleke ukuthi sigunyazwe kulo nyaka
Ngenyanga edlule, imiphumela yocwaningo lwe-SURPASS-AP-Combo yanyatheliswa ngoMeyi 25 kumagazini we-blockbuster Nature Medicine.Imiphumela ikhombisile ukuthi uma iqhathaniswa ne-insulin glargine, i-Tirzepatide ikhombise i-HbA1c engcono kanye nokuncipha kwesisindo kubantu beziguli ezinesifo sikashukela sohlobo 2 esifundeni sase-Asia-Pacific (ikakhulukazi i-China): ukwehla kwe-HbA1c kwafika ku-2.49% nokuncipha kwesisindo okungafika ku-7.2 kg. (9.4%) emavikini angu-40 okwelashwa, ukuthuthukiswa okuphawulekayo ku-lipids yegazi nomfutho wegazi, nokuphepha okuphelele nokubekezelelana kwakukuhle.
Ukuhlolwa komtholampilo kweSigaba sesi-3 se-SURPASS-AP-Combo wucwaningo lokuqala lwe-Tirzepatide olwenziwa ikakhulukazi ezigulini zaseShayina ezinesifo sikashukela sohlobo 2, oluholwa nguSolwazi Ji Linong wasePeking University People's Hospital.I-SURPASS-AP-Combo ihambisana nemiphumela yochungechunge locwaningo lomhlaba wonke lwe-SURPASS, oluphinde lufakazele ukuthi i-pathophysiology yesifo sikashukela ezigulini zaseShayina iyahambisana neyeziguli zomhlaba wonke, okuyisisekelo socwaningo kanye nokuthuthukiswa kwemithi emisha. e-China nasemhlabeni, futhi ihlinzeka ngobufakazi obuqinile bokusekela ukunikeza iziguli zaseShayina ithuba lokusebenzisa imithi yakamuva yokwelapha isifo sikashukela kanye nokusetshenziswa kwayo emtholampilo e-China ngokushesha ngangokunokwenzeka.
Isikhathi sokuthumela: Sep-18-2023